Research
Hormonal
The increased risk of breast cancer mortality is associated with five or more years of postmenopausal hormone therapy, with a relative risk of death of 1.45.
Long-term use of estrogen (5+ years) is linked to a higher risk of dying from breast cancer. This underscores the importance of regular screening and discussing the duration of therapy with your doctor.
StrongSupportsMEDIUM confidence
The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years.
Why this rating
Prospective cohort with high follow-up completeness for fatal cancer.
Source
The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women
Graham A. Colditz et al. · New England Journal of Medicine · 1995
DOI 10.1056/nejm199506153322401
cohort · n=69586Cited 1,509×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →